New tests launched in February


New Tests

In February 2023, Mayo Clinic Laboratories announced fifteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

The new tests that launched in February 2023 by Mayo Clinic Laboratories:

ATPCO | Anal ThinPrep Cytology with Human Papillomavirus (HPV) Co-Test, Varies

This test is for detection of malignant and premalignant changes. Detection of high-risk (HR) genotypes associated with the development of anal cancer. Individual genotyping of human papillomavirus (HPV)-16 and HPV-18, if present May aid in triaging men and women with positive HR-HPV but negative anal Pap smear results. The cobas HPV test is not recommended for evaluation of suspected sexual abuse.

FCXCL | CXCL9

CGRNA | Chlamydia trachomatis and Neisseria gonorrhoeae, Nucleic Acid Amplification, Varies

This test is for detecting Chlamydia trachomatis and/or Neisseria gonorrhoeae.

This test is not intended for use in medico-legal applications.

This test is not useful for the detection of other Chlamydia species.

GAPCR | Streptococcus Group A, Molecular Detection, PCR, Throat

This test is for detecting group A streptococcal infections in patients with signs and symptoms of pharyngitis using a throat swab specimen.

The test is not intended for monitoring treatment for group A Streptococcus infections.

GCRNA | Neisseria gonorrhoeae, Nucleic Acid Amplification, Varies

This test is for detecting Neisseria gonorrhoeae.

This test is not intended for use in medico-legal applications.

MCTGC | Chlamydia trachomatis and Neisseria gonorrhoeae, Miscellaneous Sites, Nucleic Acid Amplification, Varies

This test is for detecting Chlamydia trachomatis and Neisseria gonorrhoeae in non-US Food and Drug Administration-approved specimen types.

This test is not intended for use in medico-legal applications.

This test is not useful for the detection of Chlamydia pneumoniae or other Chlamydia species.

MGRNA | Neisseria gonorrhoeae, Miscellaneous Sites, Nucleic Acid Amplification, Varies

This test is for detecting Neisseria gonorrhoeae in non US Food and Drug Administration-approved specimen types.

This test is not intended for use in medico-legal applications.

MRDMR | Multiple Myeloma Minimal Residual Disease by Flow Cytometry, Bone Marrow

This test is for detecting low level (minimal residual disease) myeloma cells after therapy to confirm remission has been achieved.

MRSAP | Methicillin Resistant Staphylococcus aureus, PCR, Nasal

This test is for rapid screening test for Staphylococcus aureus nasal carriage that, if positive, indicates whether the S aureus is methicillin susceptible or resistant.

This test should not be used to guide or monitor treatment for methicillin-resistant S aureus or S aureus infections.

MSMRD | Myeloma Stratification and Risk-Adapted Therapy with Reflex to Minimal Residual Disease, Bone Marrow

This test is for risk stratification of patients with treated multiple myeloma, which can assist in determining treatment and management decisions.

MTRNA | Trichomonas vaginalis, Nucleic Acid Amplification, Varies

This test is for detecting Trichomonas vaginalis in urine or urethral swabs.

TVRNA | Trichomonas vaginalis, Nucleic Acid Amplification, Varies

This test is for detecting Trichomonas vaginalis in cervical/endocervical or vaginal specimen types.

VHPV | Human Papillomavirus (HPV) Vaginal Detection with Genotyping for High-Risk Types by PCR

This test is for detection of high-risk (HR) genotypes associated with the development of cervical cancer Aids in triaging women with abnormal Pap smear results. Individual genotyping of human papillomavirus (HPV)-16 and/or HPV-18, if present Results of HPV-16 and HPV-18 genotyping can aid in triaging women with positive HR-HPV but negative Pap smear results.

In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories:

Chantell Canfield (@chantellcanfield)

Chantell Canfield

Chantell Canfield is a web content coordinator for Mayo Clinic Laboratories. She began working for Mayo Clinic in 2021.